For novel medical devices, an early feasibility study (EFS) generally comes before a pivotal trial. That sequence isn’t arbitrary, it reflects the difference in what each study is actually built to answer.
An early feasibility study is a limited clinical investigation conducted early in device development, typically enrolling a small number of subjects to generate initial clinical safety and feasibility data (FDA, EFS Program, May 2022). A pivotal study, by contrast, is designed to collect definitive evidence of a device’s safety and effectiveness for a specified intended use (NIH Clinical Center, IDE overview). One answers “does this work safely in humans at all?” The other answers “does this work well enough to support marketing authorization?”
Getting the order wrong costs money. Launching a statistically powered pivotal study before you’ve validated basic human safety and device function is a common way to burn runway on a program that wasn’t ready for definitive endpoints.
Why sequencing is a strategic decision
The choice between EFS-first and direct pivotal isn’t just regulatory, it shapes your investor milestones, your time to first human data, and what evidence you’ll be able to use in a U.S. submission. These are the four decision nodes that determine the right path.
Four decision nodes to determine your path
Node 1: Device risk class and study significance
Higher-risk, implantable, or novel-mechanism devices carry greater uncertainty about first-in-human (FIH) safety. When your device is first-in-class or involves a mechanism never tested clinically, nonclinical data alone rarely justifies enrolling subjects in a definitive effectiveness study. An Investigational Device Exemption (IDE) under 21 CFR Part 812 is required for significant-risk device studies in the U.S.; FDA’s EFS Program is specifically designed to support IDE-based early clinical evaluation that provides proof of principle and initial clinical safety data (FDA, September 2018).
Node 2: Preclinical maturity and design finality
Ask yourself two questions: Is your GLP/bench/animal package complete enough to characterize the primary safety risks? Is the device design frozen, or are you still iterating on the core mechanism? If either answer is “not yet,” EFS-first is the appropriate path. A pivotal study requires stable endpoints, a fixed device design, and enough preclinical grounding to power a statistical hypothesis. If you’re still learning what the right endpoint even is, a pivotal protocol will be mis-scoped.
Node 3: Funding runway and time-to-milestone
Pivotal studies require statistical powering, which means larger enrollment, longer timelines, and more operational complexity. If your current runway needs to produce human evidence that supports your next financing round, an EFS can deliver proof-of-principle data in a fraction of the time and cost of a full pivotal program. This is a planning estimate, not a guarantee, but the structural difference in enrollment size and study duration is real.
Node 4: Intended U.S. regulatory pathway and evidence role
Connect the study type to what you’ll actually need for your 510(k), De Novo, or PMA submission. EFS evidence doesn’t replace definitive effectiveness data, but a well-designed EFS can refine endpoint selection, validate risk controls, and inform the statistical assumptions your pivotal study will be powered on. That’s the “bridge”, not an automatic transfer of evidence, but a structured plan for how EFS findings feed your later U.S. program.
Sequencing flowchart: EFS-first vs direct pivotal
Work through these questions in order:
-
Is the primary remaining uncertainty clinical safety, function, or feasibility, and is the design still evolving?
- Yes → EFS-first. Minimum deliverables: preclinical package gap analysis, IDE/EFS pre-submission outline, IRB (Institutional Review Board) plan under 45 CFR Part 46.
- No, proceed to question 2.
-
Is your device design stable, and does your GLP/nonclinical package address primary safety risks with enough rigor to support definitive endpoints?
- Yes → Consider direct pivotal path. Minimum deliverables: statistical analysis plan (SAP) draft, endpoint specification, and protocol architecture.
- No → Return to EFS-first.
-
Can your current budget and timeline support a multi-year, statistically powered study?
- No → EFS-first is the practical route. Use EFS to generate investor-grade proof-of-principle and refine assumptions for future pivotal planning.
- Yes, and nonclinical support is sufficient → Direct pivotal may be appropriate.
One caution: EFS-first isn’t appropriate when nonclinical evidence already resolves the clinical unknowns and the device design is fully mature. In that case, adding an EFS stage delays marketing authorization without generating meaningfully new information.
Three scenarios with checkpoints
Scenario 1: Startup with a limited budget and tight runway
Decision nodes: Novel device mechanism (Node 1 = high risk/uncertainty), preclinical package partially complete (Node 2 = design iterating), limited runway insufficient for multi-year pivotal (Node 3), targeting a future PMA (Node 4).
Recommended path: EFS-first. A small-enrollment EFS in a jurisdiction with faster ethics approval timelines can generate FIH proof-of-principle while preserving capital for the pivotal phase.
Checkpoint: Preclinical package gap list completed; evidence role for EFS documented in protocol architecture; ethics/IRB plan scope validated.
Scenario 2: High-risk implant (e.g., novel cardiovascular device)
Decision nodes: Class III or equivalent (Node 1 = requires IDE, significant risk), GLP studies done but design still being refined based on animal data (Node 2 = not design-final), multi-year runway may be available but FIH safety validation is the immediate unknown (Node 3), PMA pathway intended (Node 4).
Recommended path: EFS-first. The clinical safety and device function gap must be closed before a pivotal study can be responsibly scoped. What must be true in preclinical maturity before EFS: biocompatibility testing complete, primary failure mode characterized in animals, and device delivery/implant procedure validated in bench/animal model.
Checkpoint: Risk control validation complete; EFS protocol drafted with explicit evidence role for later pivotal SAP assumptions; ethics submission package ready.
Scenario 3: Lower-risk device with a stable design
Decision nodes: Class II equivalent (Node 1 = lower risk), bench and animal testing complete, design frozen (Node 2 = mature), adequate runway (Node 3), 510(k) or De Novo pathway (Node 4).
Recommended path: Direct pivotal (or a smaller traditional feasibility study if some clinical uncertainty remains). The nonclinical package may be sufficient to support definitive effectiveness endpoints without requiring a separate FIH proof-of-principle stage.
Checkpoint: Statistical hypothesis and primary endpoint specified; protocol architecture drafted; site selection criteria defined.
How EFS evidence can support later U.S. submissions
If your EFS is conducted outside the U.S., the data can potentially be considered by FDA under 21 CFR 812.28, which governs acceptance of foreign clinical data to support an IDE or marketing application. FDA acceptance is determined per submission, there’s no automatic pathway.
To improve defensibility, conduct the study under ISO 14155, the international standard for good clinical practice in medical device clinical investigations. Align documentation from day one: protocol, informed consent forms, monitoring and QA records, and a clinical study report (CSR) built to submission-ready standards with clear data traceability.
Operationally, this means building your “evidence drawer” at study start, not after. Every source document category that a regulatory reviewer might request should be planned before enrollment opens.
Documentation checklist to align at study start:
- Protocol with explicit evidence role statement
- Informed consent forms compliant with applicable IRB/ethics requirements (45 CFR Part 46 for U.S. sites)
- Monitoring and QA plan with deviation tracking
- Data management plan with traceability to source documents
- CSR-ready output structure and statistical analysis framework
- Data room architecture for post-study regulatory submissions
bioaccess® structures its FIH-12™ program around exactly this approach: FDA-anchored strategy combined with ISO 14155 protocol architecture and CSR/evidence package delivery as a single accountable output across nine workstreams. In selected Latin American jurisdictions, ethics and regulatory approvals have been observed in 30 to 90 days (a planning range based on experience, not a guarantee), which can support an earlier first-patient date than U.S. or EU timelines typically allow.
What you’ve accomplished and where to go next
Working through the four decision nodes and the flowchart above gives you a defensible, documented rationale for your sequencing choice. That rationale matters to investors, to ethics committees, and to FDA reviewers who will eventually evaluate your submission.
Your immediate next steps:
- Complete the decision checklist (all four nodes documented with your current answers).
- Identify preclinical readiness gaps before committing to a study type.
- Draft the evidence role statement: what you need this study to do for your next regulatory or financing milestone.
- Map the sequencing decision to your intended U.S. pathway with a team that has executed this before.
Talk with bioaccess® about whether an early feasibility study (EFS) or a pivotal path fits your device and runway.
Leave a Reply